WealthPlan Investment Management LLC reduced its position in shares of Johnson & Johnson (NYSE:JNJ – Free Report) by 53.1% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 58,570 shares of the company’s stock after selling 66,230 shares during the period. Johnson & Johnson accounts for about 1.6% of WealthPlan Investment Management LLC’s portfolio, making the stock its 23rd largest holding. WealthPlan Investment Management LLC’s holdings in Johnson & Johnson were worth $9,078,000 at the end of the most recent reporting period.
A number of other large investors have also made changes to their positions in JNJ. Sierra Capital LLC raised its stake in shares of Johnson & Johnson by 0.6% in the fourth quarter. Sierra Capital LLC now owns 10,036 shares of the company’s stock valued at $1,773,000 after acquiring an additional 61 shares in the last quarter. MTM Investment Management LLC increased its holdings in Johnson & Johnson by 0.5% in the first quarter. MTM Investment Management LLC now owns 11,283 shares of the company’s stock valued at $1,749,000 after buying an additional 61 shares during the last quarter. Lockerman Financial Group Inc. increased its holdings in Johnson & Johnson by 2.4% in the fourth quarter. Lockerman Financial Group Inc. now owns 2,684 shares of the company’s stock valued at $474,000 after buying an additional 62 shares during the last quarter. OneAscent Financial Services LLC increased its holdings in Johnson & Johnson by 3.3% in the first quarter. OneAscent Financial Services LLC now owns 1,986 shares of the company’s stock valued at $308,000 after buying an additional 63 shares during the last quarter. Finally, Addison Advisors LLC increased its holdings in Johnson & Johnson by 0.8% in the fourth quarter. Addison Advisors LLC now owns 7,862 shares of the company’s stock valued at $1,389,000 after buying an additional 64 shares during the last quarter. 67.57% of the stock is currently owned by hedge funds and other institutional investors.
Johnson & Johnson Price Performance
Shares of NYSE:JNJ opened at $172.92 on Wednesday. The company has a quick ratio of 0.88, a current ratio of 1.12 and a debt-to-equity ratio of 0.44. The company has a market cap of $449.41 billion, a P/E ratio of 35.00, a PEG ratio of 2.92 and a beta of 0.54. Johnson & Johnson has a 52 week low of $150.11 and a 52 week high of $181.04. The company has a 50-day moving average price of $165.50 and a 200 day moving average price of $161.20.
Johnson & Johnson Announces Dividend
The business also recently declared a quarterly dividend, which will be paid on Thursday, September 7th. Stockholders of record on Monday, August 28th will be given a dividend of $1.19 per share. The ex-dividend date of this dividend is Friday, August 25th. This represents a $4.76 dividend on an annualized basis and a dividend yield of 2.75%. Johnson & Johnson’s payout ratio is 96.36%.
Insider Activity
In other news, insider William Hait sold 14,698 shares of Johnson & Johnson stock in a transaction that occurred on Wednesday, July 26th. The shares were sold at an average price of $172.00, for a total transaction of $2,528,056.00. Following the completion of the sale, the insider now directly owns 87,747 shares in the company, valued at approximately $15,092,484. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. In other news, insider William Hait sold 14,698 shares of the firm’s stock in a transaction that occurred on Wednesday, July 26th. The shares were sold at an average price of $172.00, for a total transaction of $2,528,056.00. Following the completion of the transaction, the insider now directly owns 87,747 shares of the company’s stock, valued at approximately $15,092,484. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, VP Peter Fasolo sold 20,000 shares of the firm’s stock in a transaction that occurred on Tuesday, July 25th. The stock was sold at an average price of $170.32, for a total transaction of $3,406,400.00. Following the transaction, the vice president now directly owns 102,696 shares of the company’s stock, valued at $17,491,182.72. The disclosure for this sale can be found here. In the last three months, insiders sold 47,163 shares of company stock worth $7,928,856. Company insiders own 0.20% of the company’s stock.
Wall Street Analyst Weigh In
JNJ has been the topic of several recent analyst reports. Raymond James increased their target price on Johnson & Johnson from $181.00 to $184.00 and gave the company an “outperform” rating in a report on Monday, July 24th. JPMorgan Chase & Co. increased their target price on Johnson & Johnson from $175.00 to $180.00 and gave the company a “neutral” rating in a report on Friday, July 21st. Credit Suisse Group raised their price objective on Johnson & Johnson from $170.00 to $175.00 and gave the stock a “neutral” rating in a report on Friday, July 21st. Barclays raised their price objective on Johnson & Johnson from $171.00 to $175.00 and gave the stock an “equal weight” rating in a report on Monday, July 24th. Finally, Stifel Nicolaus raised their price objective on Johnson & Johnson from $165.00 to $175.00 in a report on Friday, July 21st. Eight equities research analysts have rated the stock with a hold rating, four have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $171.80.
View Our Latest Stock Analysis on Johnson & Johnson
Johnson & Johnson Profile
Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment provides skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products.
Featured Stories
- Five stocks we like better than Johnson & Johnson
- What is a Special Dividend?
- On Holding Slips Into A More Comfortable Price PointÂ
- Investing In Automotive Stocks
- 3 Growing Cannabis Stocks Ready To Bloom
- Airline Stocks: What They Are and How to Invest
- Will Meta’s Pullback Offer Buy Point After AI-Driven Surge?
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.
